MJ
Therapeutic Areas
UroGen Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ZUSDURI™ (UGN-102) | Recurrent Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer (LG-IR-NMIBC) | Commercial |
| Jelmyto® (UGN-101) | Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) | Commercial |
| UGN-103 | Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer (LG-IR-NMIBC) | Phase 3 |
| UGN-302 | High-Grade Non-Muscle-Invasive Bladder Cancer (HG-NMIBC) | Phase 2 |
| UGN-401 | Locally Advanced or Metastatic Solid Tumors | Phase 1/2 |
| UGN-501 | Urothelial Carcinoma | Preclinical |
Leadership Team at UroGen Pharma
LB
Liz Barrett
President and Chief Executive Officer
CD
Chris Degnan
Chief Financial Officer
MK
Marina Konorty
EVP, Research & Development and Technical Operations
DL
David Lin
Chief Commercial Officer
JO
Jim Ottinger
EVP, Regulatory Affairs and Quality
MP
Mark P. Schoenberg
Chief Medical Officer
TS
Timothy Simon
SVP, Business Development and Portfolio Strategy
JS
Jason Smith
General Counsel and Chief Compliance Officer